Dr. Avgeris studied Biology and received his MSc from the Faculty of Biology of the National and Kapodistrian University of Athens (NKUA). Dr. Avgeris holds a PhD degree in Clinical Biochemistry and Molecular Diagnostics from the Dept. of Biochemistry and Molecular Biology of the Faculty of Biology of NKUA. Following his PhD, he worked as PostDoc research fellow in the Dept. of Biochemistry and Molecular Biology as well as Academic Scholar of the Faculty of Biology of NKUA. During his Ph.D and PostDoc he has worked in 5 research grants from Greek-EU funded programs in the NKUA and the Biomedical Research Foundation of the Academy of Athens (BRFAA). Among others, his works have been awarded by the National Academy of Clinical Biochemistry of USA (NACB) and the Federation of European Biochemical Societies (FEBS). In 2019, Dr. Avgeris was elected Associate Professor at the School of Medicine of the National and Kapodistrian University of Athens. 

His current research is focusing on applied molecular biology and modern molecular diagnostics towards personalized and precision medicine in oncology, focusing on:
  • tumor-related non-coding RNAs (miRNAs, lncRNAs, tRFs),
  • Epigenetics (DNA methylation),
  • Epitranscriptomics (RNA epigenetics), and
  • cell-free DNA (cfDNA)/circulating-tumor DNA (ctDNA)
  • RNA biology
Links
PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Avgeris+M&sort=date
Google Scholar: https://scholar.google.com/citations?user=v6yBiJ4AAAAJ&hl=en&oi=ao
Research Gate: https://www.researchgate.net/profile/Margaritis-Avgeris-2
Orcid: https://orcid.org/0000-0002-2135-9886
Publons: https://publons.com/researcher/253544/margaritis-avgeris/
LinkedIn: https://www.linkedin.com/in/margaritis-avgeris-a4659b8b/?originalSubdoma...

Selected Publications
  • Pilala KM, Papadimitriou MA, Panoutsopoulou K, Barbarigos P, Levis P, Kotronopoulos G, Stravodimos K, Scorilas A, Avgeris M. Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome. Molecular Therapy Nucleic Acids 2022; 30:311-322. DOI: 10.1016/j.omtn.2022.10.001.
  • Papadimitriou MA, Panoutsopoulou K, Pilala KM, Scorilas A, Avgeris M. Epi-miRNAs: Modern mediators of methylation status in human cancers. WIREs RNA 2022; e1735. DOI: 10.1002/wrna.1735.
  • Avgeris M, Tsilimantou A, Levis PK, Tokas T, Sideris DC, Stravodimos K, Ardavanis A, Scorilas A. Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. British Journal of Cancer 2018; 119(12):1477-1486. DOI: 10.1038/s41416-018-0320-6.
  • Avgeris M, Tsilimantou A, Levis PK, Rampias T, Papadimitriou MA, Panoutsopoulou K, Stravodimos K, Scorilas A. Unravelling UCA1 lncRNA prognostic utility in urothelial bladder carcinoma. Carcinogenesis 2019; 40(8):965-974. DOI: 10.1093/carcin/bgz045.
  • Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, Scorilas A, Klinakis A. A new tumor suppressor role for the Notch pathway in bladder cancer. Nature Medicine 2014; 20(10):1199-205. DOI: 10.1038/nm.3678.
  • Vassilakopoulou M*, Avgeris M*, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A. Evaluation of PD-L1 expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clinical Cancer Research 2016; 22(3):704-13. *Equal contribution DOI: 10.1158/1078-0432.CCR-15-1543.
  • Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z, Kousidou E, Tzetis M, Kanavakis E, Stravodimos K, Manola KN, Pantelias GE, Scorilas A, Klinakis A. The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer. EMBO Reports 2019;20(3). pii: e46821. DOI: 10.15252/embr.201846821.
  • Panoutsopoulou K, Avgeris M, Magkou P, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Loverix L, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients. International Journal of Cancer. 2020;147(12):3560-3573. DOI: 10.1002/ijc.33182.
  • Papadimitriou MA, Avgeris M, Levis P, Papasotiriou EC, Kotronopoulos G, Stravodimos K, Scorilas A. tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5'-tRF-LysCTT Results in Disease Early Progression and Patients' Poor Treatment Outcome. Cancers (Basel) 2020;12(12):3661. DOI: 10.3390/cancers12123661.
  • Papadimitriou MA, Papanota AM, Adamopoulos PG, Pilala KM, Liacos CI, Malandrakis P, Mavrianou-Koutsoukou N, Patseas D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, Terpos E, Scorilas A. miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. British Journal of Cancer 2021; DOI: 10.1038/s41416-021-01602-8.
  • Pateras IS, Kotsakis A, Avgeris M, Baliou E, Kouroupakis P, Patsea E, Georgoulias V, Menez-Jamet J, Kinet JP, Kosmatopoulos K. Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in "Immune Desert" NSCLC. Cancers (Basel) 2021;13(7):1658. DOI: 10.3390/cancers13071658.
  • Avgeris M, Adamopoulos PG, Galani A, Xagorari M, Gourgiotis D, Trougakos IP, Voulgaris N, Dimopoulos MA, Thomaidis NS, Scorilas A. Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. Int J Mol Sci 2021;22(16):8498. DOI: 10.3390/ijms22168498.
  • Galani A, Aalizadeh R, Kostakis M, Markou A, Alygizakis N, Lytras T, Adamopoulos PG, Peccia J, Thompson DC, Kontou A, Karagiannidis A, Lianidou ES, Avgeris M, Paraskevis D, Tsiodras S, Scorilas A, Vasiliou V, Dimopoulos MA, Thomaidis NS. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. Science Total Environment 2022; 804:150151. DOI: 10.1016/j.scitotenv.2021.150151
  • Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-suppressor miR-145 results in shorter disease-free survival of prostate cancer patients. British Journal Cancer 2013;108(12):2573-81. DOI: 10.1038/bjc.2013.250.
  • Avgeris M, Mavridis K, Tokas T, Stravodimos K, Fragoulis EG, Scorilas A. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Carcinogenesis 2015; 36(5):528-37. DOI: 10.1093/carcin/bgv024.
  • Avgeris M, Kokkinopoulou I, Maratou E, Mitrou P, Boutati E, Scorilas A, Fragoulis EG, Christodoulou MI. Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome. Diabetes Res Clin Pract 2020;164:108187. DOI: 10.1016/j.diabres.2020.108187